<DOC>
	<DOC>NCT00791661</DOC>
	<brief_summary>A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe and well tolerated, based on the assessment of clinical and laboratory evaluations and adverse experiences, in Japanese participants with T2DM.</brief_summary>
	<brief_title>MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Japanese male or female between 20 to 64 years of age Diagnosis of type 2 diabetes Patient is being treated with diet and exercise alone or single oral antihyperglycemic agent Subject has a history of type 1 diabetes mellitus Subject has a clinical diagnosis of glaucoma Subject has donated blood or participated in another clinical study in the past 12 weeks Subject is a regular user of any illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>